Financial Performance - Net profit attributable to shareholders for the first quarter of 2022 was CNY 5,586,935.69, a decrease of 10.83% compared to CNY 6,265,365.91 in the same period last year[15] - Operating revenue for the first quarter of 2022 was CNY 37,694,584.15, down 1.42% from CNY 38,237,391.48 year-on-year[15] - Basic earnings per share decreased by 32.38% to CNY 0.11 from CNY 0.17 in the same period last year[15] - The company's net cash flow from operating activities for the first quarter was CNY 7,272,807.75, a decline of 3.42% compared to CNY 7,530,507.15 in the previous year[15] - Comprehensive income for Q1 2022 totaled 5,365,879.18, compared to 6,080,797.96 in Q1 2021, reflecting a decrease of about 11.8%[50] - Operating profit for Q1 2022 was 5,706,635.43, compared to 6,807,626.86 in Q1 2021, showing a decline of around 16.2%[46] - Total operating revenue for Q1 2022 was 37,674,137.74, a decrease from 38,237,391.48 in Q1 2021, representing a decline of approximately 1.5%[48] - Net profit for Q1 2022 was 5,365,879.18, down from 6,080,797.96 in Q1 2021, indicating a decrease of about 11.8%[46] Assets and Liabilities - Total assets as of March 31, 2022, amounted to CNY 379,752,076.69, reflecting a 1.10% increase from CNY 375,622,625.19 at the end of the previous year[15] - The company's total liabilities to assets ratio was 10.90% as of March 31, 2022, down from 11.35% at the end of the previous year[15] - The net assets attributable to shareholders increased to CNY 339,377,445.23, representing a 1.67% increase from CNY 333,790,509.54 at the end of the previous year[15] - Current liabilities decreased to CNY 39,239,452.20 from CNY 40,438,314.48, a reduction of approximately 2.96%[38] - Total liabilities decreased to CNY 41,389,558.88 from CNY 42,625,986.56, indicating a decline of about 2.91%[39] - Shareholders' equity increased to CNY 338,362,517.81 from CNY 332,996,638.63, showing a growth of approximately 1.10%[39] Cash Flow - Cash and cash equivalents decreased from ¥71,640,283.15 on December 31, 2021, to ¥41,570,848.36 on March 31, 2022, representing a decline of approximately 42%[37] - Operating cash inflow for Q1 2022 was CNY 46,223,409.90, a decrease of 21.0% from CNY 58,626,742.69 in Q1 2021[51] - Cash inflow from operating activities for the parent company in Q1 2022 was CNY 46,170,386.26, down from CNY 58,627,113.60 in Q1 2021[54] - The parent company's net cash flow from operating activities in Q1 2022 was CNY 6,765,897.00, a decrease from CNY 8,011,473.90 in Q1 2021[54] - Cash outflow for purchasing goods and services in Q1 2022 was CNY 24,862,533.50, down 30.2% from CNY 35,537,659.34 in Q1 2021[51] Shareholder Information - The number of ordinary shareholders as of the report date was 8,513[21] - The major shareholders include Wang Min with 26.07% and Wang Fang with 19.53% of the total shares[24] - The total shares held by the top ten shareholders amount to 37,256,377, representing 76.67% of the total shares[24] Commitments and Compliance - The company has committed to avoiding related party transactions and ensuring compliance with regulations[29] - The company has confirmed that all previously disclosed commitments are being fulfilled[29] - The company committed to avoiding all illegal occupation of funds and guarantees by the company and its subsidiaries[30] - The company has also committed to publicly disclosing information and ensuring there are no false records or misleading statements as of October 30, 2020[33] Investments and Expenses - Research and development expenses increased to 3,042,481.56 in Q1 2022 from 2,376,842.25 in Q1 2021, reflecting a growth of approximately 27.9%[46] - Long-term equity investments rose to CNY 9,637,742.33 from CNY 5,600,000.00, an increase of approximately 72.80%[42] - Investment income for Q1 2022 was 158,080.00, down from 485,846.58 in Q1 2021, indicating a decline of about 67.5%[46] Other Financial Metrics - The total non-recurring gains and losses for the first quarter amounted to CNY 378,919.17 after tax[19] - Financial expenses decreased to 392,582.84 in Q1 2022 from 492,377.92 in Q1 2021, a reduction of approximately 20.2%[46] - The company reported a credit impairment loss of 122,066.95 in Q1 2022, significantly lower than 637,683.86 in Q1 2021, a decrease of approximately 80.9%[46]
锦好医疗(872925) - 2022 Q1 - 季度财报